Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mixed-lineage leukemia and asynchronous antigen expression.

C A Hurwitz1, J Mirro

  • 1Department of Hematology/Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee.

Hematology/Oncology Clinics of North America
|August 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study.

Leukemia·2010
Same author

Mutant murine leukemia virus Gag proteins lacking proline at the N-terminus of the capsid domain block infectivity in virions containing wild-type Gag.

Virology·2006
Same author

Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study.

Journal of pediatric hematology/oncology·2001
Same author

Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2001
Same author

RNA is a structural element in retrovirus particles.

Proceedings of the National Academy of Sciences of the United States of America·2001
Same author

Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

Blood·2001
Same journal

Palliative Therapy for Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Ablative Therapies for Liver Tumors.

Hematology/oncology clinics of North America·2026
Same journal

Pathology of Liver and Biliary Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Minimally Invasive Surgery for Liver and Biliary Tract Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Surgical Considerations for Primary Liver Neoplasms.

Hematology/oncology clinics of North America·2026
Same journal

Systemic Therapy for Biliary and Liver Neoplasms: Chemotherapy and Immunotherapy.

Hematology/oncology clinics of North America·2026
See all related articles

Defining acute mixed-lineage leukemia requires strict criteria for blast cells co-expressing lymphoid and myeloid features. Identifying these leukemias and lineage switches is crucial for prognosis and targeted therapies in pediatric oncology.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Acute mixed-lineage leukemia (AMLL) lacks a universally accepted definition.
  • Blast cells co-expressing lymphoid and myeloid characteristics are key to AMLL classification.
  • Understanding AMLL is vital for prognosis and treatment strategies.

Purpose of the Study:

  • To propose strict criteria for defining AMLL based on co-expressed lymphoid and myeloid characteristics.
  • To highlight the importance of identifying AMLL and metachronous leukemia for prognostic implications.
  • To explore the potential of antigenic asynchrony in lymphoid leukemias for minimal residual disease detection.

Main Methods:

  • Utilized cytochemical, immunologic, molecular, and cytogenetic analyses.

Related Experiment Videos

  • Established criteria for diagnosing AMLL based on blast cell lineage co-expression.
  • Investigated antigenic asynchrony in leukemic lymphoblasts.

    • Main Results:

    • Proposed a strict definition for AMLL based on co-expressing lymphoid and myeloid blast cell features.
    • Emphasized the need for evidence of original clone recurrence in diagnosing metachronous leukemia.
    • Highlighted antigenic asynchrony as a potential marker for minimal residual disease detection in lymphoid leukemias.

    Conclusions:

    • Refined criteria for AMLL diagnosis are essential for accurate prognostication.
    • Identifying lineage switches and antigenic asynchrony can improve therapeutic strategies.
    • Further research into these unusual leukemias may enhance understanding of hematopoiesis, leukemogenesis, and treatment outcomes for relapsed childhood ALL.